Do triple test results predict the risks for adverse pregnancy outcomes?
INTRODUCTION
Antenatal screening tests have being used widely all over the world (1) . The triple test is performed between 14 and 21 weeks of gestational age and determine the risk for fetal chromosomal abnormalities, combining maternal serum levels of α-fetoprotein (AFP), total β-human chorionic gonadotropin (hCG) and unconjugated estriol (E 3 ) levels, and maternal age although it is not diagnostic (2) . Alvarez-Nava et al. (3) found that elevated second trimester maternal serum markers were also indicators for Turner syndrome. There have been many developments during recent years to increase the detection rate of chromosomal abnormalities. According to recent guidelines, quad marker test which includes inhibin A in addition to other markers of triple test serum markers should be recommended as a second trimester screening test. But the evidence for quad market test being superior to triple test is limited (4) .
Another benefit of the triple test is that many adverse pregnancy outcomes (APO) such as preeclampsia, gestational diabetes mellitus (GDM), intrauterine growth restriction (IUGR) may be understood with these serum markers (5) . We currently know that in case of any suspicion of APO in an early gestational week would let us recommend several precautions such as close follow-up, bed rest or aspirin (6) .
We aimed to determine the relationship between triple test results with APO and to define the cut-off values for these APO. We compared parameters of triple test serum markers and found that AFP/E 3 ratio is meaningful to determine the risk for APO.
MATERIAL AND METHODS
This is a case-control study. The triple antenatal screening test has been carried out in our hospital for many years. The results of triple test and pregnancy outcomes in 1372 pregnant women were investigated. These women were chosen from women who had triple test performed between April 2014 and April 2015, and gave birth in Kanuni Sultan Suleyman Training and Research Hospital. Inclusion criteria were viable fetus between 14 and 21 weeks of gestation, singleton pregnancy, availability of the results of triple test. We excluded multiple pregnancies, women having a fetus with known neural tube defect or any chromosomal abnormality and women with a history of APO. We did not include women who had done triple test and then not come for follow-up.
All maternal serum markers were studied with solid-phase competitive enzyme immunoassay method. All of them were converted and analyzed as multiples of the median (MoM). Fasting blood tests were taken from an antecubital vein from pregnant women between 14 and 21 weeks of gestation. Blood samples were allowed to clot for 20-30 minutes at room temperature and then centrifuged at 3000 x g for 5 minutes and frozen up to below -80°C until analysis.
Complete demographic and clinical characteristics were obtained from records, including age, weight, obstetric history, presence of any comorbid conditions, in vitro fertilization pregnancy, smoking, gestational weeks on triple test and birth, birth weight, type of delivery, gender of baby. We also investigated the association of these characteristics with APO.
Our study was designed retrospectively and conducted according to the Helsinki Declaration. There was no ethical approval because we collected data of the patients from the records in archive and we did not documented any personal information. Also in our hospital, informed consent is taken from every patient regarding the medical information, which may be used in scientific publications.
Statistical Analysis
Statistical analyses were performed with the Statistical Package for the Social Sciences (SPSS Inc; Chicago, IL, USA) statistics 22.0 version for Windows. Differences in mean values and characteristics between groups are analyzed with independent samples t-test and chi-square test. Means were presented with standard deviation (SD). p<0.05 was considered statistically significant. For the multivariate analysis, the possible factors identified with univariate analyses were further entered into the logistic regression analysis to determine independent predictors of patient outcome. Thresholds for the association of abnormal maternal serum triple analytes with APO for this study were determined by initially using receiver operating characteristics (ROC) curves to ascertain the optimal cut-off for each analyte. When a significant cut-off value was observed, the sensitivity, specificity, positive likelihood ratio values were presented. While evaluating the area under the curve, a 5% type-I error level was used to accept a statistically significant predictive value of the test variables.
RESULTS
A total of 1372 women who had triple test performed between April 2014 and April 2015 and gave birth at Kanuni Sultan Suleyman Training and Research Hospital were included in the study. The mean age of our study population was 27.9±5.6, whereas the median age was 28. According to median age, the majority of women in the group aged 28-51. The mean gestational week was 17.3±1.0 weeks during triple test, and 38.3±2.7 weeks during birth (Table-1 ). Most patients were multiparous and had vaginal delivery. 42.6% of patients gave birth by cesarean section and the most frequent indication for cesarean section was previous cesarean history (Table-2) .
Adverse pregnancy outcomes such as preeclampsia, IUGR were encountered in 113 patients (8.2% of patients). Older age women giving birth with cesarean section were more prone to (Table-4 ).
Table-5 shows the results of the binary logistic regression analysis. The AFP level was identified as the strongest factor determining the risk for APO in our study population.
DISCUSSION
Second trimester maternal serum triple screening test, is being used for the detection of risk of fetal chromosomal abnormalities, especially Down syndrome, which affects approximately 1 in 800 live-born babies. This test is applied between (7) . Besides the risk assessment for chromosomal abnormalities, many APO such as preeclampsia, GDM, IUGR can be detected with this test.
Our primary outcome defined as APO were gestational hypertension, preeclampsia, HELLP syndrome, IUGR and GDM. Preeclampsia is defined as the blood pressure ≥140/90 mmHg during pregnancy or within the first 24 hours postpartum without a history of chronic hypertension, and is diagnosed if proteinuria exists in addition to diagnostic criteria of gestational hypertension without the signs and symptoms of preeclampsia. There is hemolysis, thrombocytopenia, elevated liver function tests in HELLP syndrome which is accepted as a variant of preeclampsia. IUGR is suspected when the estimated fetal weight falls below the 10 th percentile for gestational age. Testing for GDM screening is typically performed at 24 to 28 weeks of gestation. If the screening test is positive, then a diagnostic 3-hour glucose tolerance test is performed with 100 g glucose after at least 8 hours of fasting. With abnormal fasting or any other two abnormal values, the diagnosis of GDM is confirmed (8) .
We apply triple test to all patients consulted to our clinics for control during second trimester, due to its cost-effectiveness and its high rates of detection of chromosomal abnormalities (9) . Triple test is feasible in multiple pregnancies, but we excluded the multiparous patients from our study (10) . We can also identify women with high risks for APO with the second trimester serum markers. In fact, determination of risks for said APO with the first trimester screening test is more sensible, because prevention strategies such as aspirin, bed rest are more beneficial for these pregnant women (11) . But it is not late to offer screening tests during second trimester to the patients and inform about benefits for risk assessment of APO. Yang et al. (12) evidenced that second trimester screening tests of serum markers can be helpful to identify fetal chromosomal and anatomical anomalies and to predict unfavorable pregnancy outcomes, which are similar to our results. In another study, abnormal results of second trimester screening test could be associated with APO in women with normal appearing fetus (6). Gu et al. (13) concluded that combination of parameters (pregnancyassociated plasma protein-A (PAPP-A), E 3 and AFP) are more helpful for prediction of preeclampsia than individual parameters, whereas Hume et al. (11) preferred the serum markers in early pregnancy in prediction of preeclampsia.
Decisions may vary by personal preference about having knowledge and taking precautions for APO. Our responsibility should be to inform patients about benefits of screening tests. Our aim was to emphasize the importance of these tests. In time, developments will allow us to understand which test is superior. The application of screening tests at earlier gestational weeks must be the subject for further studies.
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